It isn’t too late to sustain a 50-year-long reduction in cardiovascular disease-related deaths, according to research published in Clinical Cardiology—but with rising rates of obesity and diabetes, we’re closer than ever to reversing that progress.

The FDA published its final guidance Jan. 22 for ensuring medical devices meet “more modern safety and performance criteria” before being cleared through the agency’s 510(k) review process.

A report from Persistence Marketing Research predicts the demand for neurovascular thrombectomy devices (NTDs), particularly stent retrievers, will surge in the near future alongside a growing prevalence of cerebral infarction and ischemic stroke.

Following a series of valsartan recalls over carcinogenic impurities, at least three sellers of the popular blood-pressure medication hiked their prices, the Wall Street Journal reported.

Interventional cardiologist Kipp Webb and representatives from Montana’s Bozeman Health Deaconess Hospital entered a 19-day jury trial Jan. 17 after Webb claimed the hospital created a monopoly over cardiology services in 2011, preventing him from practicing in the area.

Copayment vouchers for P2Y12 inhibitors modestly improved the likelihood that patients would continue taking the guideline-recommended medications for one year after myocardial infarction, according to a study published in JAMA. However, patients supplied with this financial assistance didn’t see a subsequent improvement in clinical outcomes.

ST-segment elevation myocardial infarction (STEMI) survivors covered by Medicaid have lower rates of revascularization and higher rates of in-hospital mortality than their counterparts with private insurance, according to a study published in Circulation: Cardiovascular Quality and Outcomes.

High retail prices for diabetes test strips are driving a “gray market” in the U.S. as an increasing number of uninsured diabetics struggle to afford something they need as often as 10 times a day, the New York Times reports.